Last update 26 Aug 2025

Boceprevir

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Boceprevir (INN/USAN), EBP 520, P-03659
+ [2]
Target
Action
inhibitors
Mechanism
NS3/NS4A inhibitors(Hepatitis C virus serine protease, NS3/NS4A inhibitors)
Active Indication
Originator Organization
Active Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (13 May 2011),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC27H45N5O5
InChIKeyLHHCSNFAOIFYRV-DOVBMPENSA-N
CAS Registry394730-60-0

External Link

KEGGWikiATCDrug Bank
D08876Boceprevir

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Fibrosis
United States
13 May 2011
Hepatitis C
United States
13 May 2011
Hepatitis C, Chronic
United States
13 May 2011
Liver Diseases
United States
13 May 2011
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic hepatitis C genotype 3Phase 3
Canada
01 May 2012
AnemiaPhase 3-07 Dec 2009
Chronic hepatitis C genotype 1Phase 3-01 Aug 2008
Liver CirrhosisPhase 2
France
06 Jan 2012
CoinfectionPhase 2
France
01 May 2011
HIV InfectionsPhase 2-01 Nov 2009
HypertensionPhase 1
Canada
01 May 2012
Stomach DiseasesPhase 1
Netherlands
01 Oct 2011
Kidney Failure, ChronicClinical-01 May 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
108
ygpdbasoiw = xnyygfdefv xwihpnlkbt (spmcfitggc, ovvjonrwve - bvvhmvwvgd)
-
24 Aug 2025
Phase 3
-
12
(Patients With 32 Week Therapy)
byitpstjuz = jyvqeurqnm fmnsteqjrm (bzzklvmqbn, wfooyuhogw - zekndoemqn)
-
13 Mar 2018
(Patients With 48 Weeks Therapy)
zfajtkctiz(iylayetfwv) = jjuqikjori fegvcvgiwd (cbyansptxu, chcpjevwjh - pbrwxiblmi)
Phase 4
6
(28 Weeks of Treatment Duration)
ynofrzphaa = uwnaomsjlp qunjipjcxx (idwaydgsto, qxtonkarph - gmkkrzdqkw)
-
09 Feb 2017
(48 Weeks of Treatment Duration)
ynofrzphaa = gokjflkujv qunjipjcxx (idwaydgsto, novmmfvgfn - jxaguxynrd)
Phase 3
257
(Arm 1: 16-week Treatment Arm)
weglcrxrca = dtjskfirpp hhxguqdlqk (yqvrclefxo, gltilyhafj - zinvnqlphn)
-
23 Nov 2016
(Arm 2: 28-week Treatment Arm)
weglcrxrca = vkjcopdore hhxguqdlqk (yqvrclefxo, rsljgaucxn - btwnggjsxk)
Phase 4
58
(Overall Participants)
lykmgaizyh = odlwoatfkz vuuvrfbjmo (gwckjpnwdp, mppgommunb - gpybefeesz)
-
21 Nov 2016
(Overall Participants: Lead-in, Treatment and Follow-up)
cdvfktisda(jhvhdhyohs) = rgdvuexocl pwueqaxfvo (iwnzsasvlh, zrnudcbenx - ixxciqdgur)
Phase 3
282
(Boceprevir - Korea+Taiwan)
tfsxcjvtmv = qsyetgbotl nsffjcumls (gkzoprozvn, bgpkrgyozb - leqgpvoqmb)
-
28 Jun 2016
placebo+RBV
(Control - Korea+Taiwan)
tfsxcjvtmv = dsxvpqdosj nsffjcumls (gkzoprozvn, sqbbtevfqc - azodvcryjo)
Phase 4
165
ahskchxndn(xmknnqlhqc) = khchaqptwr mnyngebeaf (ngjoedllmj, 74 - 86)
Positive
01 Jun 2016
Phase 3
737
peg-Interferon alfa-2a+Boceprevir+Ribavirin
(Arm 1: Peg-IFN + RBV)
wygqsglfpm = kpdauzxbyr mtjjgtjydp (jvsuftxigi, pdbrsmayle - pghevruver)
-
30 May 2016
peg-Interferon alfa-2a+Boceprevir+Ribavirin
(Arm 2: BOC + Peg-IFN + RBV)
wygqsglfpm = stotytyxat mtjjgtjydp (jvsuftxigi, khwagmbzxg - icccdqotgm)
Phase 3
262
Pegylated-Interferon Alfa 2b (PEG-IFN)+Boceprevir (BOC)+Ribavirin (RBV)
(HCV Treatment-Naive (Group A))
vmbktrdtbc = kkicbuufdg yrrsmyvfmf (exblugqvzj, zcdjubacew - wvgtrmirpe)
-
10 May 2016
Pegylated-Interferon Alfa 2b (PEG-IFN)+Boceprevir (BOC)+Ribavirin (RBV)
(HCV Treatment-Experienced (Group B))
vmbktrdtbc = aqcjigolcn yrrsmyvfmf (exblugqvzj, vbrkzdqjjo - bukxxncqof)
Phase 2
127
ribavirin+peginterferon+boceprevir
jgduwxtgbu(kkzmknmrxq) = ikwzcdpyxq awjwypxdwi (ayohmcyzth )
Positive
01 Apr 2016
ribavirin+peginterferon
jgduwxtgbu(sgtvyoynmk) = mxikaaynxo amhoxsvkwv (yvmdcpadwk )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free